301 results about "Pulmonary emphysema" patented technology

An apparatus and method of detecting COPD and in particular, emphysema utilizes a change in acoustic transmission characteristics of a lung due to e.g. the appearance of fenestrae (perforations) in the alveoli of the lung. The use of acoustic signals may provide good sensitivity to the existence of alveolar fenestrae, even for microscopic emphysema, and the appearance and increase in fenestrae may be determined by monitoring acoustic transmission characteristics such as, for example, an increase in acoustic signal velocity and velocity dispersion, and/or a change in attenuation. A transmitter may be located in e.g. the supra-clavicular space and receivers may be mounted on the chest. Measurements may be correlated between pairs of receivers to determine acoustic transmission profiles.

The capsule for treating asthma, pulmonary emphysema and SARS is developed based on the principle that the Chinese medicine and the Western medicine are complementary and synergistic, and compounded with several kinds of Chinese medicines and Western medicines. It can kill bacteria, resist virus, eliminate circulating disturbance and regulate immunity, and suitable for various people in different disease stages. It has high and stable curative effect. In addition, it has also certain treating effect on hypertension, angiosclerosis, wind-wetness Bi syndrome, etc.

The present invention discloses an oral solid preparation containing ambroxol hydrochloride and salbutamol active components. It is formed from ambroxol hydrochloride, salbutamol and auxiliary material according to a certain mixing ratio. Said oral solid preparation has the obvious synergistic action for remitting the symptoms of dyspnea, etc. due to respiratory tract obstruction diseases of bronchial asthma, chronic bronchitis and pulmonary emphysema, etc.

Disclosed herein is the treatment of vision loss in a mammal by transplanting an effective amount of hNT-Neuron cells. The treatment can be accomplished by injecting the cells into the retinal area of the eye. Additionally, the cells can be injected into the visual cortex of the brain. Conditions to be treated are vision loss due to optic nerve damage, including glaucoma, optic nerve sheath meningioma and glioma, Graves' ophthalmopathy, benign or malignant orbital tumors, metastatic lesions, tumors arising from the adjacent paranasal sinuses or middle cranial fossa, giant pituitary adenomas, brain tumors or abscesses, cerebral trauma or hemorrhage, meningitis, arachnoidal adhesions, pseudotumor cerebri, cavernous sinus thrombosis, dural sinus thrombosis, encephalitis, space-occupying brain lesions, severe hypertensive disease or pulmonary emphysema.

The invention relates to an image report based CT image emphysema automatic labeling method. The method includes the following steps: (1) accomplishing an image report, CT image sequence inputting andimage standardization preprocessing in an input module; (2) extracting the characteristic information, namely the information about emphysema description, in the image report in a phonetic and semantic extraction module according to the technical and rule pattern matching technology of a dictionary; (3) performing regional division on a lung in an emphysema focus extraction module, and performingcluster analysis in a lung area to extract emphysema focus; and (4) obtaining the CT threshold value of each area through calculation according to calculating results of the step 3, labelling the emphysema area of each area in an output and display module, displaying the emphysema areas in a CT image, and giving a quantitative analysis report of lung function. The advantages of the method are that processes during emphysema diagnosis and treatment can be simplified, and medical expenses of patients can be reduced.

Surfactant protein D (SP-D) is a 43-kDa member of the collectin family of collagenous lectin domain-containing proteins that is expressed in epithelial cells of the lung. The SP-D gene was targeted by homologous recombination in embryonic stem cells that were used to produce SP-D (−/−) mice. The SP-D (−/−) deficiency caused inflammation, increased oxidant production by isolated alveolar macrophages, abnormal surfactant structure and levels, and decreased SP-A expression. Therefore, disclosed is the SP-D (−/−) mouse as an excellent model for emphysema. Also included are models for testing emphysema therapies in the mouse model, methods for using SP-D protein or DNA as a treatment for emphysema and pulmonary infections, and diagnosis.

The invention relates to a pharmaceutical composition for treating lung diseases, and belongs to the field of traditional Chinese medicines. The drug is an orally administered preparation prepared from medical materials and pharmaceutically common auxiliary materials by a pharmaceutically common process, wherein the medical materials include honeysuckle, nepeta, peucedanum, fried radix cynanchi, almond, fritillaria, red tangerine peel, forsythia, fried stemona, aster, platycodon root, American ginseng, fried lily, reed root, fried ephedra, costazia bone, fructus perillae, fried loquat leaf, fried poppy shell, ledebouriella seseloides, skullcap, gypsum and licorice. Clinical tests prove that the pharmaceutical composition has good treatment effects on emphysema, pulmonary heart disease, asthma, phlegmatic chronic trachitis and other lung diseases.

The current invention provide novel compounds, methods of treating or preventing emphysema, cancer and dermatological disorders, pharmaceutical compositions suitable for the treatment or prevention of emphysema, cancer and dermatological disorders and methods for delivering formulations into the lung of a mammal suffering from emphysema, cancer and dermatological disorders.

The present invention relates to compounds according to formula (I), a process for preparing them, the intermediate compounds of the process and the use of the compounds in the manufacture of a medicament for use in treating diseases such as ARDS, pulmonary emphysema, bronchitis, bronchiectasis, COPD, asthma and rhinitis. The compounds are beta2 adrenoreceptor agonists.

The invention relates to a traditional Chinese medicine decoction for treating senile chronic bronchitis complicated pulmonary emphysema, which is prepared from the raw medicines by weight: 15g of root of hairy asiabell, 15g of Astragalus membranaceus, 15g of white atractylodes rhizome, 15g of Tuckahoe, 15g of Angelica sinensis, 15g of Ligusticum wallichii, 15g of herba patriniae, 10g of fructus forsythia, 10g of roasted semen raphani, 10g of radix paeoniae alba, 10g of Pinellia ternate, 10g of radix asteris, 10g of flos farfarae, 10g of pulp of dogwood fruit, 10g of dried tangerine or orange peel, 10g of polygala tenuifolia, 10g of inula flower, 10g of rhizoma zingiberis, 10g of bulbus fritillariae cirrhosae, 10g of Schisandra chinensis, 10g of folium eriobotryae, 10g of radix ophiopogonis and 10g of Fructus Trichosanthis. The traditional Chinese medicine decoction is low-cost and convenient to use, has remarkable effects of relieving a cough, eliminating phlegm and clearing heat, is capable of reducing recurrence rate of bronchitis and pulmonary emphysema, relieving symptoms and has the effective rate of 96.8%.

The invention discloses a Bambuterol Hydrochloride oral disintegration tablet, wherein the principal drug employs Bambuterol Hydrochloride, the auxiliary materials include lactose, mannitol, crystalline cellulose, low replacement methylcellulose propylene glycol ether, cross bonding polyvinyl pyrrolidon, sodium hydrogen carbonate, citric acid, Aspartame, perfume compound, and magnesium stearate. The tablet has good treatment action for bronchial asthma, chronic bronchitis and pulmonary emphysema.

The invention provides a novel application of fritillaria alkaloid in preparation of medicines for preventing or treating a chronic respiratory disease. Monomeric compounds contained in the fritillaria alkaloid comprise chuanbeinone, sipeimine, sipeimine nitrogen oxide, sipeimine glucoside, yibei alkali, yibeinoside, isoverticine, isoverticine-beta-N-oxide, peimisine, hupehenine, peimine and peinine. The fritillaria alkaloid provided by the invention is capable of significantly improving the lung function of a chronic obstructive pulmonary disease, blocking formation of pulmonary emphysema, improving the pathological conditions of the lung, reducing inflammatory cytokines plasma levels of the lung and peripheral blood, and regulating the oxidant factor action of the lung and the activity of matrix metalloproteinase. The fritillaria alkaloid provided by the invention is stable in quality, safe to use, easy to control; the preparation method is simple; and mass production and clinical application are facilitated.

The invention discloses a kind of baicalein derivatives and a preparation method and application thereof. Pharmacological tests prove that the compounds have the obvious function of dilating bronchi and can be used to prepare the medicines used for preventing or curing chronic obstructive emphysema caused by bronchial constriction.